MHRA grants marketing authorisation for Novartis’ Pluvicto
12th August 2022 Uncategorised 0Radioligand therapy involves patients with advanced prostate cancer in Great Britain
More: MHRA grants marketing authorisation for Novartis’ Pluvicto
Source: News
